Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:CLDX NASDAQ:INVA NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$13.00-1.5%$0.00$11.06▼$63.00$254.15M1.5235,340 shs61,103 shsCLDXCelldex Therapeutics$22.39+1.5%$20.87$14.40▼$47.00$1.49B1.13967,075 shs500,675 shsINVAInnoviva$19.28-1.1%$19.91$16.67▼$22.00$1.21B0.37712,899 shs351,059 shsNVAXNovavax$7.21+0.6%$6.89$5.01▼$17.81$1.16B2.696.14 million shs4.32 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma-1.05%+3.12%-12.00%-98.28%-98.28%CLDXCelldex Therapeutics-1.56%-5.57%+7.61%+13.77%-39.99%INVAInnoviva-0.36%-0.41%-7.14%+5.41%+13.44%NVAXNovavax+2.43%+2.87%+11.86%+14.72%-48.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCrescent Biopharma3.3755 of 5 stars3.80.00.03.73.31.70.6CLDXCelldex Therapeutics2.1633 of 5 stars4.41.00.00.02.50.00.0INVAInnoviva4.1706 of 5 stars3.50.00.04.22.71.71.9NVAXNovavax4.4215 of 5 stars3.11.00.04.72.10.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.50Strong Buy$25.6797.44% UpsideCLDXCelldex Therapeutics 2.89Moderate Buy$50.11123.83% UpsideINVAInnoviva 3.00Buy$40.33109.15% UpsideNVAXNovavax 2.25Hold$15.86119.81% UpsideCurrent Analyst Ratings BreakdownLatest CBIO, INVA, NVAX, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025CBIOCrescent BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.006/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$22.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10K25,415.00N/AN/A$8.24 per share1.58CLDXCelldex Therapeutics$7.02M211.70N/AN/A$11.26 per share1.99INVAInnoviva$358.71M3.38$3.38 per share5.71$11.03 per share1.75NVAXNovavax$682.16M1.71N/AN/A($3.89) per share-1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/ACLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A12.44N/A-16.15%15.77%8.41%7/30/2025 (Estimated)NVAXNovavax-$187.50M$2.652.7090.180.0638.14%-115.51%29.99%8/14/2025 (Estimated)Latest CBIO, INVA, NVAX, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLDXCelldex Therapeutics-$0.86N/AN/AN/A$1.13 millionN/A8/14/2025Q2 2025NVAXNovavax-$0.12N/AN/AN/AN/AN/A7/30/2025Q2 2025INVAInnoviva$0.43N/AN/AN/A$87.10 millionN/A5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A2.292.29CLDXCelldex TherapeuticsN/A21.6721.67INVAInnoviva0.402.482.30NVAXNovavaxN/A2.062.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%CLDXCelldex TherapeuticsN/AINVAInnoviva99.12%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma8.70%CLDXCelldex Therapeutics4.40%INVAInnoviva2.25%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5019.55 million17.85 millionNo DataCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableCBIO, INVA, NVAX, and CLDX HeadlinesRecent News About These CompaniesBank of America Lowers Novavax (NASDAQ:NVAX) Price Target to $9.003 hours ago | marketbeat.comNovavax (NVAX) Price Target Lowered by B of A Securities | NVAX Stock News3 hours ago | gurufocus.comHussman Strategic Advisors Inc. Grows Stock Position in Novavax, Inc. (NASDAQ:NVAX)July 19 at 8:01 AM | marketbeat.comNovavax Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 17, 2025 | marketwatch.comNovavax (NVAX) Rises Higher Than Market: Key FactsJuly 15, 2025 | msn.com45,000 Shares in Novavax, Inc. (NASDAQ:NVAX) Purchased by DekaBank Deutsche GirozentraleJuly 15, 2025 | marketbeat.comNovavax (NVAX) Rises Higher Than Market: Key FactsJuly 14, 2025 | zacks.comIs Trending Stock Novavax, Inc. (NVAX) a Buy Now?July 14, 2025 | zacks.comBTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PTJuly 13, 2025 | insidermonkey.com13 Cheap Stocks with Huge Upside PotentialJuly 12, 2025 | insidermonkey.comNovavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Hold" by BrokeragesJuly 12, 2025 | marketbeat.comDespite Revenue Jump, Novavax Appears Immune To Long-Term GrowthJuly 11, 2025 | seekingalpha.com2 Beaten-Down Stocks That Haven't Hit Rock Bottom YetJuly 11, 2025 | fool.comCiti Initiates Coverage of Novavax (NVAX) With a Sell RatingJuly 10, 2025 | insidermonkey.comNovavax (NASDAQ:NVAX) Trading 7.7% Higher - Here's What HappenedJuly 8, 2025 | marketbeat.comVontobel Holding Ltd. Lowers Position in Novavax, Inc. (NASDAQ:NVAX)July 8, 2025 | marketbeat.comNovavax Inc. Research & Ratings | NVAX - Barron'sJuly 6, 2025 | barrons.comNovavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comRFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine ApprovalJuly 3, 2025 | benzinga.comRFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientistsJuly 3, 2025 | fortune.comModerna’s Shares Gain in Premarket as New Flu Shot Shows Promising ResultsJuly 1, 2025 | tokenist.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBIO, INVA, NVAX, and CLDX Company DescriptionsCrescent Biopharma NASDAQ:CBIO$13.00 -0.20 (-1.52%) As of 03:44 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Celldex Therapeutics NASDAQ:CLDX$22.39 +0.33 (+1.49%) Closing price 03:58 PM EasternExtended Trading$22.46 +0.07 (+0.32%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$19.28 -0.22 (-1.11%) Closing price 03:58 PM EasternExtended Trading$19.28 0.00 (-0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Novavax NASDAQ:NVAX$7.21 +0.04 (+0.61%) Closing price 03:58 PM EasternExtended Trading$7.16 -0.06 (-0.76%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.